Search results
Results from the WOW.Com Content Network
(Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech.
COVID-19 vaccine manufacturer Moderna has filed lawsuits against both Pfizer and BioNTech over alleged patent violations pertaining to its mRNA technology.
The lawsuits said that Promosome discussed its technology with representatives from Moderna and BioNTech between 2013 and 2016. Promosome had asked the court for a share of royalties from the shots.
In November 2024, British pharmaceutical company GlaxoSmithKline (GSK) filed a lawsuit against Moderna Inc. in a U.S. federal court in Delaware, alleging that Moderna's COVID-19 vaccine Spikevax and RSV vaccine mResvia infringe on GSK’s patents related to messenger RNA (mRNA) technology. According to the complaint, Moderna's use of lipid ...
[23] [24] The vaccine technology, for antigen production and use, is given patent-free to manufacturers, although Baylor College receives a fee. [ 17 ] [ 25 ] [ 26 ] The evaluation of adjuvant components for use in a RBD based vaccine was partially enabled by NIH funding [ 27 ] along with prior funding to support development of the CpG adjvuant ...
The VICP was adopted in response to concerns over the pertussis portion of the DPT vaccine. [1] Several U.S. lawsuits against vaccine makers won substantial awards. Most makers ceased production, and the last remaining major manufacturer threatened to do so. [1] The VICP uses a no-fault system for resolving vaccine injury claims. [1]
For premium support please call: 800-290-4726 more ways to reach us
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).